omeprazole has been researched along with Exanthem in 9 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute generalized exanthematous pustulosis (AGEP) comprises a group of eruptions characterized by several small sterile pustules over an erythematous-edematous skin." | 5.35 | [Acute generalized exanthematous pustulosis induced by omeprazole]. ( Martínez-Peñuela Virseda, JM; Nantes Castillejo, O; Valcayo Peñalba, A; Zozaya Urmeneta, JM, 2008) |
| "Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
| "Omeprazole is a proton pump inhibition and ranitidine is an H2 histamine receptor antagonist widely used in the treatment of gastroesophageal reflex disease, peptic ulcer disease, Zollinger-Ellison syndrome and as a protector of the gastric mucosae." | 1.46 | Occupational contact allergy to omeprazole and ranitidine. ( Herrera-Mozo, I; Martí-Amengual, G; Sanz-Gallen, P, 2017) |
| "Acute generalized exanthematous pustulosis (AGEP) comprises a group of eruptions characterized by several small sterile pustules over an erythematous-edematous skin." | 1.35 | [Acute generalized exanthematous pustulosis induced by omeprazole]. ( Martínez-Peñuela Virseda, JM; Nantes Castillejo, O; Valcayo Peñalba, A; Zozaya Urmeneta, JM, 2008) |
| "Omeprazole was used in 90% of the patients; lansoprazole, in 7%." | 1.34 | Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. ( El-Serag, HB; Hassall, E; Kerr, W, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herrera-Mozo, I | 1 |
| Sanz-Gallen, P | 1 |
| Martí-Amengual, G | 1 |
| Kardaun, SH | 1 |
| Tupker, RA | 1 |
| Chularojanamontri, L | 1 |
| Jiamton, S | 1 |
| Manapajon, A | 1 |
| Suvanasuthi, S | 1 |
| Kulthanan, K | 1 |
| Dhana, N | 1 |
| Jongjarearnprasert, K | 1 |
| Wu, CJ | 1 |
| Hsu, PI | 1 |
| Lo, GH | 1 |
| Lo, CC | 1 |
| Lin, CK | 1 |
| Shie, CB | 1 |
| Peng, NJ | 1 |
| Tseng, HH | 1 |
| Jou, HS | 1 |
| Tsai, PM | 1 |
| Chen, A | 1 |
| Chen, JL | 1 |
| Lai, KH | 1 |
| Jacobs-Kosmin, D | 1 |
| Derk, CT | 1 |
| Sandorfi, N | 1 |
| Hassall, E | 1 |
| Kerr, W | 1 |
| El-Serag, HB | 1 |
| Nantes Castillejo, O | 1 |
| Zozaya Urmeneta, JM | 1 |
| Valcayo Peñalba, A | 1 |
| Martínez-Peñuela Virseda, JM | 1 |
| Dewerdt, S | 1 |
| Vaillant, L | 1 |
| Machet, L | 1 |
| de Muret, A | 1 |
| Lorette, G | 1 |
| Wong, BC | 1 |
| Wong, WM | 1 |
| Yee, YK | 1 |
| Hung, WK | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Li, KF | 1 |
| Lau, P | 1 |
| Fung, FM | 1 |
| Tong, TS | 1 |
| Lai, KC | 1 |
| Hu, WH | 1 |
| Yuen, MF | 1 |
| Hui, CK | 1 |
| Lam, SK | 1 |
2 trials available for omeprazole and Exanthem
| Article | Year |
|---|---|
Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2004 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
7 other studies available for omeprazole and Exanthem
| Article | Year |
|---|---|
Occupational contact allergy to omeprazole and ranitidine.
Topics: Dermatitis, Occupational; Eczema; Exanthema; Histamine H2 Antagonists; Humans; Male; Middle Aged; Om | 2017 |
Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) induced by omeprazole.
Topics: Adult; Aged; Drug Eruptions; Exanthema; Female; Humans; Omeprazole; Proton Pump Inhibitors | 2012 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Cas | 2012 |
Pantoprazole and perinuclear antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Aged; Anti-Ulcer Agents; Antibodies, Antineu | 2006 |
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Distribution; Child; Child, Preschool; Cohort Studies; | 2007 |
[Acute generalized exanthematous pustulosis induced by omeprazole].
Topics: Acute Disease; Aged; Aged, 80 and over; Drug Eruptions; Exanthema; Female; Humans; Male; Middle Aged | 2008 |
Acute generalized exanthematous pustulosis induced by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Exanthema; Female; Humans; Lan | 1997 |